OC
AVDL

Oppenheimer & Co’s Avadel Pharmaceuticals AVDL Stock Holding History

Oppenheimer & Co’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-43,853
Closed -$670K – 1569
2025
Q3 		$670K Sell
43,853
-22,701
-34% -$295K 0.01% 1074
2025
Q2 		$589K Sell
66,554
-1,355
-2% -$11.9K 0.01% 1080
2025
Q1 		$532K Buy
67,909
+841
+1% +$7.04K 0.01% 1057
2024
Q4 		$705K Buy
67,068
+33,963
+103% +$412K 0.01% 934
2024
Q3 		$434K Buy
33,105
+2,780
+9% +$42.3K 0.01% 1092
2024
Q2 		$426K Sell
30,325
-6,770
-18% -$110K 0.01% 1054
2024
Q1 		$627K Sell
37,095
-816
-2% -$12.2K 0.01% 913
2023
Q4 		$535K Sell
37,911
-2,000
-5% -$23.5K 0.01% 943
2023
Q3 		$411K Buy
39,911
+5,663
+17% +$75.8K 0.01% 1016
2023
Q2 		$564K Buy
34,248
+10,890
+47% +$142K 0.01% 925
2023
Q1 		$214K Buy
+23,358
New +$192K ﹤0.01% 1239
2020
Q4 		– Sell
-27,904
Closed -$141K – 1344
2020
Q3 		$141K Buy
27,904
+5,090
+22% +$37K ﹤0.01% 1205
2020
Q2 		$184K Buy
+22,814
New +$201K ﹤0.01% 1137

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer & Co's AVDL Position: Q4 2025 in Review

Oppenheimer & Co sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 43,853 shares — an estimated $670K sold.

Oppenheimer & Co first reported a position in AVDL in Q2 2020 and held it in 13 quarters. The position peaked at $705K in Q4 2024. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • Oppenheimer & Co reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 43,853 Avadel Pharmaceuticals shares in Q4 2025, an estimated $670K.
  • Oppenheimer & Co first reported a position in Avadel Pharmaceuticals in Q2 2020 and held it in 13 quarters.
  • Oppenheimer & Co's Avadel Pharmaceuticals position peaked at $705K in Q4 2024.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Oppenheimer & Co's 13F filing for Q4 2025, filed 2 Feb 2026.